• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢他啶-阿维巴坦耐药与 258 型序列型中由 pKpQIL 质粒衍生物介导的基因拷贝数增加有关。

Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 .

机构信息

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Laboratory of Clinical Pathology, Microbiology, and Virology, IRCCS-ISMETT, Palermo, Italy.

出版信息

Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01816-19.

DOI:10.1128/AAC.01816-19
PMID:31964792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7179273/
Abstract

This study reports on the characterization of two ceftazidime-avibactam (CZA)-resistant KPC-producing strains (KP-14159 and KP-8788) sequentially isolated from infections occurred in a patient never treated with CZA. Whole-genome sequencing characterization using a combined short- and long-read sequencing approach showed that both isolates belonged to the same ST258 strain, had altered outer membrane porins (a truncated OmpK35 and an Asp137Thr138 duplication in the L3 loop of OmpK36), and carried novel pKpQIL plasmid derivatives (pIT-14159 and pIT-8788, respectively) harboring two copies of the Tn KPC-3-encoding transposon. Plasmid pIT-8788 was a cointegrate of pIT-14159 with a ColE replicon (that was also present in KP-14159) apparently evolved during infection. pIT-8788 was maintained at a higher copy number than pIT-14159 and, upon transfer to DH10B, was able to increase the CZA MIC by 32-fold. The present findings provide novel insights about the mechanisms of acquired resistance to CZA, underscoring the role that the evolution of broadly disseminated pKpQIL plasmid derivatives may have in increasing the gene copy number and KPC-3 expression in bacterial hosts. Although not self-transferable, similar elements, with multiple copies of Tn and maintained at a high copy number, could mediate transferable CZA resistance upon mobilization.

摘要

本研究报告了两株头孢他啶-阿维巴坦(CZA)耐药产 KPC 株(KP-14159 和 KP-8788)的特征,这些菌株是从未接受过 CZA 治疗的患者感染中连续分离出来的。使用短读长和长读长测序相结合的全基因组测序特征表明,这两种分离株均属于同一 ST258 株,其外膜孔蛋白发生了改变(OmpK35 截断和 OmpK36 L3 环中的 Asp137Thr138 重复),并携带新型 pKpQIL 质粒衍生物(分别为 pIT-14159 和 pIT-8788),分别携带两个 Tn KPC-3 编码转座子。质粒 pIT-8788 是 pIT-14159 的一个 cointegrate,带有 ColE 复制子(也存在于 KP-14159 中),显然是在感染过程中进化而来的。pIT-8788 的拷贝数高于 pIT-14159,并且在转移到 DH10B 后,能够将 CZA 的 MIC 增加 32 倍。本研究结果提供了关于获得性 CZA 耐药机制的新见解,强调了广泛传播的 pKpQIL 质粒衍生物的进化可能在增加细菌宿主中基因拷贝数和 KPC-3 表达方面的作用。虽然不能自我转移,但类似的元素,具有多个 Tn 拷贝,并以高拷贝数维持,在发生可移动化时可能介导可转移的 CZA 耐药性。

相似文献

1
Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 .头孢他啶-阿维巴坦耐药与 258 型序列型中由 pKpQIL 质粒衍生物介导的基因拷贝数增加有关。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01816-19.
2
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
3
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
4
Acquisition of a Stable and Transferable -Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing During Treatment.在治疗过程中,携带低适应性成本的稳定且可转移的头孢他啶/阿维巴坦耐药阳性质粒导致 KPC-2 产酶株获得耐药性。
Front Cell Infect Microbiol. 2021 Jul 20;11:658070. doi: 10.3389/fcimb.2021.658070. eCollection 2021.
5
Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.肺炎克雷伯菌中因孔蛋白突变和KPC-3表达增加导致对头孢他啶-阿维巴坦耐药
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00537-17. Print 2017 Jun.
6
Molecular Mechanisms Driving the Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.KPC-71 介导的对头孢他啶-阿维巴坦耐药性发展的分子机制在治疗碳青霉烯类耐药肺炎克雷伯菌感染中的作用。
mSphere. 2021 Dec 22;6(6):e0085921. doi: 10.1128/mSphere.00859-21.
7
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染:流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
8
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.KPC-53,一种源自临床的KPC-3变体,对头孢他啶-阿维巴坦敏感性降低。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01429-20.
9
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.对头孢他啶-阿维巴坦的耐药性是由于产孔蛋白缺陷的肺炎克雷伯菌中 KPC 的转位和增加的外排活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00989-17. Print 2017 Oct.
10
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.头孢他啶-阿维巴坦对一组碳青霉烯类耐药肠杆菌科挑战株的活性:OmpK36 L3 改变和具有头孢他啶水解活性的β-内酰胺酶导致 MIC 值升高。
Int J Antimicrob Agents. 2020 Jul;56(1):106011. doi: 10.1016/j.ijantimicag.2020.106011. Epub 2020 May 15.

引用本文的文献

1
evolution of ceftazidime-avibactam resistance in -positive potentially linked to PBP3 insertion and mutations in and PBP2.头孢他啶-阿维巴坦在[具体细菌名称]中的耐药性演变可能与PBP3插入以及[相关基因名称]和PBP2中的突变有关。 (你提供的原文中“ -positive ”和“ ”部分信息缺失,我按通用形式补充了相关表述以让译文完整)
JAC Antimicrob Resist. 2025 Aug 1;7(4):dlaf137. doi: 10.1093/jacamr/dlaf137. eCollection 2025 Aug.
2
Emergence of KPC-8-producing infection without prior exposure to ceftazidime/avibactam: the threat of infections by ceftazidime/avibactam-resistant KPC variants.在未预先接触头孢他啶/阿维巴坦的情况下出现产KPC-8感染:头孢他啶/阿维巴坦耐药KPC变体感染的威胁。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0149424. doi: 10.1128/aac.01494-24. Epub 2025 Apr 22.
3
Emergence and characterization of IncFII/IncR plasmids with multiple 5,692 bp- -bearing tandem repeats in ceftazidime/avibactam non-susceptible strains.在对头孢他啶/阿维巴坦不敏感菌株中出现并鉴定携带多个5,692 bp串联重复序列的IncFII/IncR质粒。
Front Microbiol. 2025 Apr 3;16:1534631. doi: 10.3389/fmicb.2025.1534631. eCollection 2025.
4
The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020.监测一种新型抗生素的重要性:2016年至2020年英格兰头孢他啶/阿维巴坦的使用情况及耐药性经验
Euro Surveill. 2025 Apr;30(14). doi: 10.2807/1560-7917.ES.2025.30.14.2400399.
5
Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing Klebsiella pneumoniae.产KPC肺炎克雷伯菌中质粒携带的柠檬酸铁转运系统赋予的头孢地尔耐药性
Emerg Infect Dis. 2025 Jan;31(1):123-124. doi: 10.3201/eid3101.241426.
6
Overexpression of caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant .串联扩增导致的过表达有助于产超广谱β-内酰胺酶和耐碳青霉烯的 对头孢他啶/阿维巴坦的耐药性。
Emerg Microbes Infect. 2024 Dec;13(1):2426481. doi: 10.1080/22221751.2024.2426481. Epub 2024 Nov 14.
7
Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy to during treatment of ST11 carbapenem-resistant .治疗 ST11 碳青霉烯类耐药肠杆菌科细菌时,由于双拷贝到的突变导致头孢他啶-阿维巴坦耐药性的进化。
mSystems. 2024 Oct 22;9(10):e0072224. doi: 10.1128/msystems.00722-24. Epub 2024 Sep 17.
8
Genomic characterization of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) strains circulating in three university hospitals in Northern Italy over three years.三年间意大利北部三家大学医院流行的产碳青霉烯酶肺炎克雷伯菌(KPC-Kp)菌株的基因组特征。
Antimicrob Resist Infect Control. 2024 Jul 3;13(1):70. doi: 10.1186/s13756-024-01429-x.
9
Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Infections.基于三级医疗的头孢他啶-阿维巴坦耐药碳青霉烯类耐药感染临床特征及结局的回顾性队列研究
Crit Care Res Pract. 2024 Jun 5;2024:3427972. doi: 10.1155/2024/3427972. eCollection 2024.
10
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.β-内酰胺酶抑制剂作为增效剂在针对革兰氏阴性菌的抗菌化疗中的作用。
Antibiotics (Basel). 2024 Mar 15;13(3):260. doi: 10.3390/antibiotics13030260.

本文引用的文献

1
Population structure of KPC carbapenemase-producing in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity.长期急性护理康复机构中产 KPC 碳青霉烯酶的 人群结构:与局部高度流行相关的克隆群 101 的一个新谱系的鉴定。
Microb Genom. 2020 Jan;6(1). doi: 10.1099/mgen.0.000308.
2
Resistance to ceftazidime-avibactam and underlying mechanisms.对头孢他啶-阿维巴坦的耐药性及其机制。
J Glob Antimicrob Resist. 2020 Sep;22:18-27. doi: 10.1016/j.jgar.2019.12.009. Epub 2019 Dec 19.
3
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染:流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
4
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.β-内酰胺/β-内酰胺酶抑制剂复方制剂在治疗革兰氏阴性菌感染方面的最新进展。
Expert Opin Pharmacother. 2019 Dec;20(17):2169-2184. doi: 10.1080/14656566.2019.1660772. Epub 2019 Sep 9.
5
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
6
OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo.OmpK36 介导的碳青霉烯类耐药削弱了 ST258 型肺炎克雷伯菌在体内的毒力。
Nat Commun. 2019 Sep 2;10(1):3957. doi: 10.1038/s41467-019-11756-y.
7
Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread.欧洲耐碳青霉烯类肺炎克雷伯菌的流行是由医院内传播驱动的。
Nat Microbiol. 2019 Nov;4(11):1919-1929. doi: 10.1038/s41564-019-0492-8. Epub 2019 Jul 29.
8
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
9
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.头孢他啶-阿维巴坦:治疗严重革兰氏阴性细菌感染的综述。
Drugs. 2018 Apr;78(6):675-692. doi: 10.1007/s40265-018-0902-x.
10
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.肺炎和肾脏替代治疗是耐碳青霉烯类肠杆菌科感染患者使用头孢他啶-阿维巴坦治疗失败和耐药的危险因素。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02497-17. Print 2018 May.